This population epidemiology study examines associations between phases of nonpharmaceutical public health interventions (social distancing, centralized quarantine, home confinement, and others) and rates of laboratory-confirmed COVID-19 infection in Wuhan, China, between December 2019 and early March 2020.
This population cohort study uses national Finnish birth registry data to assess associations between antenatal corticosteroid treatment to accelerate fetal maturation and mental and behavioral disorders in term and preterm children.
This systematic review and meta-analysis examines whether blood pressure lowering is associated with a reduced risk of dementia or cognitive impairment.
This study characterizes the prevalence of reverse-transcriptase polymerase chain reaction results positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients presenting with influenzalike illness who underwent nasopharyngeal swab testing for influenza and respiratory syncytial virus over 4 days in March 2020.
This study describes findings of novel coronavirus testing on pooled nasopharyngeal and bronchoalveolar lavage samples taken from patients who had negative results by routine respiratory virus testing to see if pooling samples could increase testing throughput and efficiency and facilitate early detection of community COVID-19 transmission.
This study uses data from the National Institutes of Infectious Diseases Japan to compare weekly influenza activity in the 2019/2020 vs the 2014-2019 seasons given mitigation strategies taken in 2020 to limit the spread of COVID-19.
This study uses US commercial health plan insurance data to characterize coverage for biosimilar drugs compared with reference products.
This Viewpoint discusses public health strategies necessary for the US to relax its mitigation strategies—most notably expanded testing, isolation, and contact-tracing in ways that avoid stigmatization of vulnerable populations—and proposes investing returns from a reopened economy to finance testing and public health infrastructure.
This Viewpoint discusses the long history of racial inequities that cause black populations in US cities to bear a disproportionate burden of COVID-19 illness and mortality and calls for a renewed commitment to eliminating disparities that have been made so starkly visible by the pandemic.
This Viewpoint discusses the challenges of accurately modeling the COVID-19 pandemic and reviews principles that will make some models more useful than others, such as use of granular local data when available, regular updating and revision, and specification of uncertainty around estimates.
This Viewpoint discusses the tensions between evaluating treatments (learning) and just treating patients (doing) during the coronavirus disease 2019 (COVID-19) pandemic, and proposes actions the clinical research and practice communities can take to support each other’s imperatives so that both can “learn from doing” in a more integrated patient care approach.
This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform their clinical use.
This Viewpoint discusses the risks to patients and public health posed by the FDA’s politically pressured Emergency Use Authorization (EUA) of chloroquine and hydroxychloroquine for COVID-19 treatment, and proposes principles to follow to ensure new therapies are studied properly and quickly to maximize benefits and minimize risks to patients.
This Viewpoint discusses the legal risks to health care workers and hospital systems from withdrawing or withholding ventilation from COVID-19 patients and cites a Maryland statute that offers legal immunity to clinicians making good faith decisions under emergency conditions as an example for other states to follow.
This Viewpoint reviews notable examples of clinical trial misconduct identified by routine US Food and Drug Administration (FDA) clinical trial site inspections and argues that making inspection reports publicly available on the agency’s and trial registry websites is important to maintaining the integrity of clinical research.
This narrative medicine essay emphasizes the undue disease burden carried by minority populations in the COVID-19 pandemic and proposes collection and reporting of data by race/ethnicity and multilingual targeted educational efforts delivered by celebrities or faith leaders as first steps to reduce the imbalance.
This narrative review summarizes current evidence regarding the pathogenesis, clinical presentation, diagnosis, and treatments of plaque psoriasis.
This JAMA Insights Clinical Update reviews the diagnosis and management of kidney stones and proposes a treatment algorithm based on imaging findings, symptom control, and risk of recurrence.
This Medical Letter review summarizes the mechanism of action and drug interactions of drospirenone, a new progestin-only oral contraceptive, and compares it with norethindrone, its competitor.
This Medical News article discusses how antibody tests should—and should not—be used during the SARS-CoV-2 pandemic.
This Arts and Medicine feature tallies the appearance of infectious disease outbreaks in cinema since 1914, and identifies common themes, such as stigmatization and physician heroism, that characterize the films.
This JAMA Patient Page describes the test for coronavirus disease 2019 (COVID-19), current guidelines for determining who should be tested, reasons for slow adoption of testing in the US, and potential drawbacks of alternate tests.
This JAMA Patient Page describes how the novel coronavirus that causes COVID-19 is transmitted and provides measures people can take while grocery shopping, unpacking groceries, and preparing food to minimize the risk of being infected.
Create a personal account or sign in to: